Tripotassium dicitratobismuthate 120mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tripotassium dicitratobismuthate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
480 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · Trials: 1 · 1954–2026
Showing the 50 most relevant studies, sorted by most relevant.
R. S. Lanigan, T. A. Yamarik
International Journal of Toxicology, 2002
Derrick F. Martin, Stephen May, D. Tweedle, et al.
Lancet, 1981
S. Lam, N. W. Lee, J. Koo, et al.
Gut, 1984
K. Okada, J. Ossaka
Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry, 1980
I. Hamilton, H. O’connor, N. C. Wood, et al.
Gut, 1986
Himani Singh, Qammer Majid, Richu, et al.
Journal of Chemical & Engineering Data, 2023
S. Dill, J. Payne-James, J. Misiewicz, et al.
Gut, 1990
- Pyloric Antrum
- Helicobacter pylori
- Dyspepsia
Shunjun Wang, Huayang Li, Quan Liu, et al.
International heart journal, 2024
Sanghun Yun, Adèle Jane Chabert, Holger Militz
Materials, 2024
Wood modification has been explored in various ways to enhance dimensional stability and reduce flammability, with a focus on environmentally friendly treatments to meet market demands. This study aimed to investigate the efficacy of new, potential fire-retardant materials. Specifically, the study examined the combination of tripotassium citrate (TPC), a water-soluble and bio-based fire retardant, with sorbitol and citric acid (SorCA), an eco-friendly thermosetting resin previously studied. While TPC is known to control combustion, its application in wood modification has not been thoroughly researched. To assess the fixation and flammability of these fire retardants, tests were conducted on Scots Pine (Pinus sylvestris L.), including chemical analysis, dimensional stability, mechanical properties, flame retardancy, and leaching tests. The combination of SorCA and TPC showed high weight percent gain (WPG) values; however, leaching and anti-swelling efficiency (ASE) tests revealed challenges in fixation stability. The dynamic mechanical properties were reduced, whereas the static strength values were in the same range compared with untreated wood. While TPC exhibited high flame retardancy prior to leaching, its efficacy diminished post-leaching, underscoring challenges in fixation and the need for improved retention strategies. Bunsen burner tests conducted on leached specimens indicated enhanced performance even under severe leaching conditions as per the EN 84:2020 procedure. However, cone calorimetry measurements showed less favorable outcomes, emphasizing the necessity for further investigation into optimizing TPC retention and enhancing treatment efficacy.
Abstract licence: CC BY 4.0
D. Wardana, F. Firmansyah, Widayana Tri Meiliya, et al.
Journal of Student Research, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.